US20190194619A1 - Platform for activation and expansion of virus-specific t-cells - Google Patents

Platform for activation and expansion of virus-specific t-cells Download PDF

Info

Publication number
US20190194619A1
US20190194619A1 US16/331,494 US201716331494A US2019194619A1 US 20190194619 A1 US20190194619 A1 US 20190194619A1 US 201716331494 A US201716331494 A US 201716331494A US 2019194619 A1 US2019194619 A1 US 2019194619A1
Authority
US
United States
Prior art keywords
cells
virus
peptides
stimulating
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/331,494
Other languages
English (en)
Inventor
Cliona M. Rooney
Natalia Lapteva Doyle
Sandhya Sharma
Dimitrios Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Priority to US16/331,494 priority Critical patent/US20190194619A1/en
Assigned to BAYLOR COLLEGE OF MEDICINE reassignment BAYLOR COLLEGE OF MEDICINE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOYLE, NATALIA LAPTEVA, ROONEY, CLIONA M., SHARMA, SANDHYA, WAGNER, Dimitrios
Publication of US20190194619A1 publication Critical patent/US20190194619A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present disclosure concerns at least the fields of immunology, cell biology, molecular biology, and medicine, including cancer medicine.
  • Antigen-specific T-cell activation and expansion requires 3 signals.
  • Signal 1 requires the T-cell receptor (TCR) to bind its cognate peptide-MHC complex.
  • Signal 2 requires stimulation of costimulatory receptors on the T-cell surface, and signal 3 is derived from cytokines.
  • the signals are required about once every 7 to 14 days to maintain the expansion of antigen-specific T-cells in vitro. In the absence of any one of these signals, T-cells will fail to proliferate and may become anergic or die.
  • T-cell Tumor-induced T-cell anergy. Circulating T-cells have been anergized by tumors and are difficult to expand from the blood of cancer patients;
  • DCs are potent antigen-presenting cells, but their numbers are limiting; they do not divide and their monocyte precursors less than 10% of blood mononuclear cells (PBMCs). Large amounts of blood would be required to obtain sufficient DCs for T-cell expansion (300 mLs to 1 liter of blood).
  • LCLs Autologous EBV-transformed B-lymphoblastoid cells lines (LCLs) are also excellent antigen-presenting cells, but it takes at least 6 weeks to establish LCLs from patients and LCLs express highly immunogenic EBV antigens that compete with weaker EBV and non-EBV antigens.
  • the present disclosure addresses a variety of issues associated with antigen-specific T-cell activation and expansion and provides relief for a long-felt need in the art to treat virus-associated diseases and malignancies with effective immunotherapies.
  • the present disclosure is directed to methods and compositions that concern immune system cells that immunogenically recognize particular targets.
  • the present invention concerns the development of virus-specific T cells (VSTs) (that may also be referred to as virus antigen-specific T cells or antigen-specific T cell) that target a biological moiety that elicits an immune response in an individual.
  • VSTs virus-specific T cells
  • the present disclosure concerns the development of VSTs that target a viral antigen, including a viral disease-associated antigen.
  • Embodiments of the disclosure include production of cells that are CD8+ T cells, CD4+ T cells, and cells that do no kill but produce one or more cytokines.
  • a mixture of cytotoxic T-cells is produced, and the mixture targets more than one viral antigen, including more than one antigen of more than one virus, in some cases.
  • the virus is not human papilloma virus (HPV).
  • Embodiments of the disclosure concern the generation and/or expansion of non-HPV-specific T-cells.
  • Embodiments of the disclosure concern methods and compositions for providing therapy to individuals infected with a non-HPV virus or that have virus-associated diseases and malignancies that are not associated with HPV, including cancers associated with certain viruses.
  • the disclosure regards methods and compositions for adoptive cellular immunotherapy that can target virus-associated medical conditions and are therapeutic therefor.
  • the present disclosure concerns the development of a plurality of T-cells that target antigens from EBV, CMV, adenovirus, vaccinia virus, HIV, and/or VZV, for example.
  • the present disclosure provides significant and non-obvious improvements on methods for generating T cell lines with specificity against antigens from EBV, CMV, adenovirus, vaccinia virus, and/or VZV, for example, wherein the virus is not HPV.
  • an individual is in need of the methods and/or compositions of the invention.
  • an individual has been exposed to EBV, CMV, adenovirus, vaccinia, and/or VZV, for example (the presence of which may or may not be known for the individual), or the individual is suspected of having been exposed to or at risk for being exposed to EBV, CMV, adenovirus, vaccinia virus, and/or VZV, for example.
  • the individual has or is suspected of having or is at risk for having disease associated with EBV, CMV, adenovirus, vaccinia, and/or VZV, or has been vaccinated with EBV, CMV, adenovirus, VZV or vaccinia virus, for example.
  • certain antigen(s) associated with EBV, CMV, adenovirus, vaccinia, and/or VZV are presented to APCs in the form of one or more peptides that span some or all of certain antigen(s).
  • the antigenic peptides may be provided to the APCs in a library of peptide mixtures, which may be referred to as pepmixes.
  • pepmixes there is pooling of a variety of pepmixes for exposure to the APCs.
  • APCs that present the antigens on MHC molecules may be exposed to peripheral blood T-cells under certain conditions to result in stimulation of T-cells specific for the certain viral antigen(s).
  • peripheral blood cells such as peripheral blood T-cells
  • the method comprises stimulating peripheral blood T-cells with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15 and, in at least some cases, in the absence of one or more other cytokines, such as IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV.
  • IL interleukin
  • Methods for stimulating T-cells specific for a non-HPV virus or for an antigen from a non-HPV virus include stimulating T-cells specific for the virus or for the antigen with antigen presenting cells in the presence of IL-7 and IL-15, and optionally in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of the virus.
  • T-cells for non-HPV virus-associated disease comprising the step of stimulating peripheral blood T-cells with antigen presenting cells in the presence of one or more of interleukin IL-7 and IL-15 and, in at least some cases, optionally in the absence of one or more other cytokines, such as IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV, wherein the stimulating produces T-cells therapeutic for virus-associated diseases and malignancies that are not HPV-associated diseases.
  • there are methods of producing therapeutic T-cells for virus-associated diseases and malignancies other than HPV-associated diseases comprising the step of stimulating T-cells specific for the virus or for a viral antigen with antigen presenting cells in the presence of one or more of interleukin IL-7 and IL-15, and optionally in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequences that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV, wherein the stimulating produces T-cells therapeutic for one or more virus-associated diseases and malignancies.
  • the peripheral blood T-cells being stimulated are obtained from a prior stimulation of peripheral blood cells, such as stimulating peripheral blood cells with antigen presenting cells in the presence of IL-7 and IL-15, and in at least some cases in the presence of one or more other cytokines, such as IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV.
  • peripheral blood cells such as stimulating peripheral blood cells with antigen presenting cells in the presence of IL-7 and IL-15, and in at least some cases in the presence of one or more other cytokines, such as IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV.
  • the methods may further comprise stimulating peripheral blood cells with antigen presenting cells in the presence of IL-7 and IL-15, and in at least some cases in the presence of IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV, to produce peripheral blood T-cells.
  • the one or more peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus that is not HPV.
  • the one or more peptides may be a library of peptides, which may also be referred to as a collection of peptides.
  • the method may produce T-cells specific for EBV, CMV, adenovirus, vaccinia, and/or VZV or for an antigen from EBV, CMV, adenovirus, Vaccinia, and/or VZV.
  • the method may expand a population of T-cells present in the peripheral blood T-cells that are specific for EBV, CMV, adenovirus, vaccinia, and/or VZV or for an antigen from EBV, CMV, adenovirus, vaccinia, and/or VZV.
  • APCs used in one or more methods of the disclosure include monocytes, dendritic cells (DC), B-Blasts (BB), and/or PBMCs, for example.
  • the antigen presenting cells are activated T-cells.
  • the stimulation of T-cells specific for a virus other than HPV or for an antigen other than one from HPV is not a first stimulation step.
  • the T-cells being stimulated cells may be the product of a prior stimulation.
  • stimulation of T-cells specific for a virus other than HPV or for an antigen other than HPV comprises stimulating T-cells specific for the virus or for the viral antigen with antigen presenting cells in the presence of interleukin (IL)-7, IL-15, and in the presence of one or more types of co-stimulatory cells.
  • IL interleukin
  • the method may produce T-cells specific for a non-HPV virus or for an antigen that is not an HPV antigen. In some embodiments the method may expand a population of T-cells specific for a virus or for an antigen other than HPV.
  • stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 optionally occurs in the absence of IL-2. In some embodiments stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 optionally occurs in the absence of at least IL-4; although in some cases IL-4 is added, for example to increase CD4+ T cells. In some embodiments stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 occurs optionally in the absence of IL-6. In some embodiments stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 but alternatively may occur in the absence of IL-7 and/or IL-15.
  • stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 optionally occurs in the absence of IL-12. In some embodiments stimulation of peripheral blood T-cells in the presence of IL-7 and IL-15 optionally occurs in the absence of IL-21.
  • the peripheral blood T-cells utilized in methods of the disclosure may be present in a population of peripheral blood mononuclear cells (PBMCs) or are obtained or isolated therefrom.
  • PBMCs peripheral blood mononuclear cells
  • the PBMCs in the population may be non-adherent PBMCs, or may be CD45RA-depleted PBMCs (for example, to eliminate a combination of Tregs, NK cells and na ⁇ ve T-cells).
  • the antigen presenting cells may be dendritic cells, B-blasts, or PBMCs, for example.
  • Methods of the present disclosure include methods of producing therapeutic T-cells for virus-associated diseases and malignanices that are not HPV.
  • the stimulation of cells may produce T-cells that are therapeutic for virus-associated diseases and malignancies that are not HPV-associated diseases.
  • a method of producing therapeutic T-cells for HPV-associated diseases is provided, the method comprising:
  • stimulating peripheral blood cells comprising stimulating peripheral blood T-cells with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15 and optionally in the absence of IL-6 and/or IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a non-HPV virus; or
  • the antigen presenting cells used in (i) and (ii) are monocytes, dendritic cells (DC) B-Blasts (BB) or PBMCs. In some embodiments the antigen presenting cells used in (iii) are activated T-cells, dendritic cells (DC), B-Blasts (BB) or PBMCs. In some embodiments the antigen presenting cells used in (iii) are different than the antigen presenting cells used in (i) and/or (ii). In preferred embodiments the antigen presenting cells used in (iii) are activated T-cells.
  • stimulation occurs in the presence of co-stimulatory cells.
  • the co-stimulatory cells are one or more cell types selected from the group consisting of CD80+ cells, CD86+ cells, CD83+ cells, 4-1BBL+ cells, and a combination thereof.
  • the co-stimulatory cells may be CD80+/CD86+/CD83+/4-1BBL+ cells.
  • the co-stimulatory cells may be HLA-negative lymphoblastoid cells.
  • methods of the present disclosure are for producing T-cells specific for EBV, CMV, adenovirus, Vaccinia, and/or VZV. In some particular embodiments methods of the present disclosure are for producing T-cells specific for diseases and malignanices associated with EBV, CMV, adenovirus, Vaccinia, and/or VZV.
  • peripheral blood T-cells may be obtained from an individual that is known to be infected or suspected of being infected or vaccinated with EBV, CMV, adenovirus, vaccinia, and/or VZV.
  • Antigen presenting cells may be obtained from an individual that is known to be infected or suspected of being infected or vaccinated with EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • the method may occur in the absence of exposing the T-cells produced by the method to activated B cells that were previously exposed to a library of peptides.
  • antigen presenting cells may be autologous or allogeneic to an individual intended to be treated with the therapeutic T-cells obtained.
  • the one or more peptides comprise sequence that corresponds at least part to the sequence of one or more proteins of EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • the peptides may correspond to a contiguous amino acid sequence present within the viral protein.
  • a peptide may have a length of at least or no more than 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length, or of 15 amino acids in length.
  • the collection of peptides may form a library and peptides in the library may overlap in sequence with other peptides by any suitable amount, including 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids, for example.
  • the peptides may comprise sequence that corresponds to the viral protein.
  • T-cells produced by the methods of the present disclosure may be isolated and/or purified, e.g., isolated/purified from other cells.
  • a therapeutically effective amount of T-cells produced by the methods of the present disclosure are provided to an individual that has been exposed to a virus that is not HPV, or that has a virus-associated disease that is not from HPV.
  • T-cells produced by the methods of the present disclosure are provided for use in the treatment of virus-associated disease that is not from HPV.
  • the use of T-cells produced by the method of the present disclosure are provided for use in the manufacture of a medicament for use in the treatment of virus-associated disease that is not HPV.
  • the methods of the disclosure encompass the use of viruses to promote the expansion of VSTs modified with one or more engineered receptors, for example chimeric antigen receptors (CARs).
  • CARs chimeric antigen receptors
  • the virus was VZV and the VSTs were VZV-specific (VZVSTs)
  • a VZV vaccine e.g., ZOSTAVAX or VARIVAX
  • the VSTs were specific for an oncolytic virus such as adenovirus, maraba virus or vaccinia or VSV
  • the oncolytic virus (OV) could not only kill tumor cells, but also stimulate CAR-modified T-cells specific for that oncolytic virus.
  • the CAR-modified OV-specific T cells could then kill uninfected or metastatic tumors cells via the CAR.
  • the individual to be treated may be a human.
  • the individual may be a patient.
  • the individual may have been exposed to EBV, CMV, adenovirus, vaccinia virus, and/or VZV, or has a disease associated with EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • the disease may be a neoplasm, such as a cancer of any kind.
  • the individual may have received, be receiving, or will receive an additional therapy for the disease including, where appropriate, an additional cancer therapy, such as surgery, radiation, hormone therapy, chemotherapy, immunotherapy, or a combination thereof.
  • an additional cancer therapy such as surgery, radiation, hormone therapy, chemotherapy, immunotherapy, or a combination thereof.
  • the individual may be determined as having virus-associated cancer that is not from HPV.
  • Methods according to the present disclosure that involve steps of cell stimulation may be performed in vitro or ex vivo.
  • in vitro is intended to encompass studies with materials, biological substances, cells and/or tissues in laboratory conditions or in culture.
  • Ex vivo refers to something present or taking place outside an organism, e.g. outside the human or animal body, which may be on tissue (e.g. whole organs) or cells taken from the organism.
  • a method for stimulating peripheral blood cells comprising stimulating peripheral blood T-cells with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of one or more viruses that are not HPV.
  • IL interleukin
  • there is a method of producing viral antigen-specific T-cells comprising the step of stimulating a population of peripheral blood T-cells with antigen presenting cells in the presence of IL-7 and IL-15 (for example, ⁇ 100 ng/mL), wherein the antigen presenting cells are or were previously exposed to a library of peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of one or more viruses that are not HPV.
  • IL-7 and IL-15 for example, ⁇ 100 ng/mL
  • a population of peripheral blood T-cells have reduced levels, compared to normal levels, of one or more of the following: 1) NK cells; 2) na ⁇ ve cells that can grow as bystander cells; and/or 3) T-regulatory cells, for example when CD45RA+ cells have been depleted from a starting PBMC or apheresis product.
  • PBMCs or peripheral blood T-cells obtained therefrom are subject to a step of reducing the levels of one or more of the following: 1) NK cells; 2) na ⁇ ve cells that can grow as bystander cells; and/or 3) T-regulatory cells.
  • Peripheral blood T-cells may be present in a population of peripheral blood mononuclear cells (PBMCs) or are obtained or isolated therefrom.
  • PBMCs or an apheresis product may be depleted of one or more of the following: 1) NK cells; 2) na ⁇ ve cells that can grow as bystander cells; and/or 3) T-regulatory cells.
  • the PBMCs may be CD45RA-depleted PBMCs.
  • PBMCs in the population may be non-adherent PBMCs.
  • the PBMCs may be depleted of myeloid cells that are suppressive myeloid cells, for example by adherence or by other depletion methods.
  • Viruses encompassed by the disclosure include those from the family Herpesviridae or is a poxvirus, adenovirus, polyomavirus, lentivirus, rhabdovirus or other oncolytic virus.
  • the virus is selected from the group consisting of Epstein-Barr virus (EBV), Cytomegalovirus (CMV), adenovirus, vaccinia virus, and/or Varicella zoster virus (VZV), HIV, influenza, marabavirus vesicular stomatitis virus or any other oncolytic virus.
  • Antigen presenting cells utilized in methods of the disclosure may be dendritic cells or PBMCs, in specific embodiments.
  • a stimulating step occurs in the absence of IL-6, IL-12, IL-2, IL-4, IL-21, or a combination thereof.
  • a stimulating step occurs in the presence of costimulatory cells, such as costimulatory cells that are CD80+, CD86+, CD83+, 4-1BBL+, or a combination thereof, or wherein the costimulatory cells are HLV-negative lymphoblastoid cells.
  • the stimulating may occur in the presence of activated T-cells, dendritic cells, PBMCs, or HLA-negative costimulatory cells.
  • the stimulating may occur in the presence of activated T-cells, dendritic cells, PBMCs, or HLA-negative costimulatory cells, the stimulating step is not a first stimulation step.
  • Activated T-cells may be autologous to the individual. Stimulating may occur in the presence of pepmixes, pepmix-pulsed autologous activated T-cells, in the presence of HLA-negative costimulatory cells, or both.
  • the stimulating step is not a first stimulation step. In such cases, two stimulations are performed and the second stimulation occurs in the presence of costimulatory cells and pepmix-pulsed (autologous activated T cells (AATCs).
  • AATCs autologous activated T cells
  • Peptide libraries utilized in methods of the disclosure may comprise peptides of at least or no more than 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acids in length.
  • the peptide library comprises peptides of 15 amino acids in length and/or peptides in the library overlap in sequence with other peptides by 11 amino acids.
  • T-cells produced by a first stimulating step are subject to one or more subsequent stimulating steps, such as a subsequent stimulating step that occurs in the presence of IL-7 and IL-15.
  • a subsequent stimulating step may occur in the presence of activated T-cells, costimulatory cells, IL-7, and/or IL-15.
  • the method occurs in the absence of exposing the T-cells produced by the method to activated B cells that were previously exposed to a library of peptides.
  • cells produced by the method are modified to express a gene product from an expression vector, such as modified to express a chimeric antigen receptor, ⁇ T-cell receptor, or combination thereof.
  • a therapeutically effective amount of T-cells produced by the method are provided to an individual that has been exposed to EBV, CMV, adenovirus, vaccinia virus, HIV, and/or VZV, that is seropositive for EBV, CMV, adenovirus, vaccinia virus, HIV, and/or VZV, or that has disease associated with EBV, CMV, adenovirus, vaccinia virus, HIV, and/or VZV.
  • the individual is determined as having a medical condition associated with EBV, CMV, adenovirus, vaccinia virus, HIV, and/or VZV.
  • the cancer is a non-viral cancer.
  • one or more steps of the method lack the presence of exogenously added IL-4, IL-2, or both.
  • there is a method for stimulating T-cells specific for a virus other than HPV comprising stimulating T-cells specific for the virus with antigen presenting cells in the presence of IL-7 and IL-15 and in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus other than HPV.
  • a method of producing therapeutic T-cells for a virus-associated disease or a non-virus-associated disease comprising the step of stimulating T-cells specific for a virus other than HPV with antigen presenting cells in the presence of one or more of IL-7 and IL-15 and in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus other than HPV, wherein the stimulating produces T-cells therapeutic for the virus-associated disease or malignancy.
  • the disclosure encompasses at least the following:
  • a method for stimulating peripheral blood cells comprising stimulating peripheral blood T-cells with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of one or more viruses that are not human papillomavirus (HPV).
  • IL interleukin
  • HPV human papillomavirus
  • a method of producing viral antigen-specific T-cells comprising the step of stimulating a population of peripheral blood T-cells with antigen presenting cells in the presence of IL-7 and IL-15, wherein the antigen presenting cells are or were previously exposed to a library of peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of one or more viruses that are not HPV.
  • PBMCs or peripheral blood T-cells obtained therefrom are subject to a step of reducing the levels of one or more of the following: 1) NK cells; 2) na ⁇ ve cells that can grow as bystander cells; and/or 3) T-regulatory cells.
  • influenza is from the family Herpesviridae or is a poxvirus, adenovirus, polyomavirus, lentivirus, rhabdovirus or other oncolytic virus.
  • the virus is selected from the group consisting of Epstein-Barr virus (EBV), Cytomegalovirus (CMV), adenovirus, Vaccinia, and/or Varicella zoster virus (VZV), HIV, influenza, marabavirus vesicular stomatitis virus and an oncolytic virus.
  • EBV Epstein-Barr virus
  • CMV Cytomegalovirus
  • VZV Varicella zoster virus
  • HIV influenza
  • marabavirus vesicular stomatitis virus an oncolytic virus.
  • peripheral blood T-cells are present in a population of peripheral blood mononuclear cells (PBMCs) or are obtained or isolated therefrom.
  • PBMCs peripheral blood mononuclear cells
  • PBMCs or apheresis product are depleted of one or more of the following: 1) NK cells; 2) na ⁇ ve cells that can grow as bystander cells; and/or 3) T-regulatory cells.
  • PBMCs are CD45RA-depleted PBMCs and/or are CD45RO-depleted PBMCs.
  • costimulatory cells are CD80+, CD86+, CD83+, 4-1BBL+, or a combination thereof, or wherein the costimulatory cells are HLV-negative lymphoblastoid cells.
  • the stimulating step is not a first stimulation step.
  • peptide library comprises peptides of at least or no more than 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acids in length.
  • a method for stimulating T-cells specific for a virus other than HPV comprising stimulating T-cells specific for the virus with antigen presenting cells in the presence of IL-7 and IL-15 and in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus other than HPV.
  • a method of producing therapeutic T-cells for a virus-associated disease or a non-virus-associated disease comprising the step of stimulating T-cells specific for a virus other than HPV with antigen presenting cells in the presence of one or more of IL-7 and IL-15 and in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of a virus other than HPV, wherein the stimulating produces T-cells therapeutic for the viral-associated disease.
  • FIG. 1 illustrates general embodiments of virus-specific T-cell (VST) generation methods of the disclosure.
  • FIG. 2 demonstrates improved specificity of methods of the disclosure that employ IL-7 and IL-15 as compared to known methods that employ IL-4 and IL-7.
  • FIG. 3 shows improved specificity of lymphoma patient EBVSTs grown in the presence of IL-7 and IL-15.
  • FIG. 4 demonstrates that high doses of IL-15 increase specificity of VSTs.
  • FIG. 5 shows that high dose of IL-15 increases central memory EBVSTs.
  • FIG. 6 shows excessive NK-cell outgrowth in EBVSTs from some patients.
  • FIG. 7 illustrates generation of pepmix-activated EBVSTs from CD45RA-depleted PBMCs.
  • FIG. 8 demonstrates that CD45RA depletion decreases the frequency of CD3-CD56+ NK cells in EBVSTs expanded from healthy donors.
  • FIG. 9 shows that removal of CD45RA+ cells increases proliferation of EBVSTs.
  • FIG. 10 demonstrates that CD45RA depletion enhanced the fold expansion of EBVSTs.
  • FIG. 11 shows CD45RA depletion enhances antigen specificity of EBVSTs at the end of a second stimulation (at day 16).
  • FIG. 12 demonstrates CD45RA depletion enhances antigen specificity of EBVSTs.
  • FIG. 13 demonstrates increased antigen specificity of CD45RA depleted EBVSTs sustained after a third stimulation.
  • FIG. 14 demonstrates CD45RA depletion decreases NK cell population outgrowth in lymphoma patient EBVSTs.
  • FIG. 15 shows CD45RA depletion increased the frequency of antigen specific T-cells in lymphoma patient EBVSTs.
  • FIG. 16 demonstrates CD45RA depletion increased antigen specificity in EBVSTs from lymphoma patients.
  • FIG. 17 shows the effect of CD45RA depletion on proliferation of lymphoma patients' EBVSTs.
  • FIG. 18 demonstrates that CD45RA-depletion enhanced cytolytic activity against pepmix-pulsed autologous activated T-cells (aATCs).
  • FIG. 19 illustrates an embodiment of generation of T-cells specific for EBV, CMV, Adenovirus, BK virus, and HHV6 (multivirus-specific T-cells).
  • FIG. 20 demonstrates expansion of multivirus-specific T-cells.
  • FIG. 21 shows antigen specificity of multivirus-specific T-cells.
  • FIG. 22 demonstrates proliferation of VZV-specific VSTs after a first stimulation.
  • FIG. 23 shows expansion of VZVSTs after a second stimulation.
  • FIG. 24 demonstrates specificity of the VZVSTs after a first stimulation (at day 8).
  • FIG. 25 demonstrates specificity of VZVSTs after a second stimulation (at day 16).
  • FIG. 26 illustrates manufacturing of HIV-specific T-cells from HIV seropositive donors.
  • FIG. 27 shows optimal expansion with K562 cells in a second stimulation.
  • FIG. 28 demonstrates that in the presence of K562, HIV antigen-specific T cells (HIVSTs) expanded to clinically relevant numbers after only two stimulations.
  • HIVSTs HIV antigen-specific T cells
  • FIG. 29 shows that HIVSTs are specific for multiple HIV antigens.
  • FIG. 30 demonstrates that HIVSTs comprise mixed CD4+ and CD8+ T cells.
  • FIG. 31 demonstrate that HIVSTs can lyse antigen-pulsed and HIV-infected targets.
  • the present disclosure concerns the production and use of therapeutic T-cells for individuals that are in need of EBV-, CMV-, adenovirus-, vaccinia virus-, and/or VZV-specific T-cells, including for treating medical conditions associated with one or more of these viruses in an individual.
  • the disclosure concerns the production and use of therapeutic T-cells for a non-viral cancer; in such cases, one or more CARs are expressed in the VSTs and vaccination or oncolytic viruses are used to stimulate the CAR-VSTs via their T-cell receptors.
  • therapeutic T-cells are generated upon stimulation of APCs in the presence of IL-7 and IL-15, wherein the APCs were previously exposed to a peptide library directed to one or more viral antigens.
  • the present disclosure addresses challenges related to adoptive T cell transfer.
  • the inventors have evaluated various combinations of cytokines and determined that at least in some cases a high dose of IL-15 combined with IL-7 facilitates the expansion of anergic antigen-specific T-cells ( FIG. 2 ).
  • the first stimulation antigen-specific T-cells are activated by pulsing PBMCs with overlapping peptide libraries (pepmixes that comprise 15mer amino acids overlapping by 11 amino acids and spanning the proteins of interest, for example) in the presence of IL7 (10 ng per mL) and IL15 (100 ng per mL).
  • the inventors have evaluated antigens from several different viruses to make virus-specific T-cells (VSTs).
  • an antigen-presenting cell complex in which autologous activated T-cells pulsed with peptides provide signal 1 (binding of T-cell receptor (TCR) to its cognate peptide-MHC complex), and an HLA-negative LCL, provides co-stimulation (signal 2).
  • An alternative artificial costimulatory cell line is the HLA-negative K562 cell line genetically modified to express CD80, CD86, CD83 and 4-1BB ligand, for example. In this case co-stimulation is provided in trans, on a different cell type. In such cases, HLA antigens must be absent because these molecules are potent antigens and can activate allospecific T-cells, and EV-LCLs naturally express a range of costimulatory molecules.
  • PBMCs may be depleted of CD45RA+ T-cells. This depletes not only NK cells but also na ⁇ ve T-cells and natural T regulatory cells. VSTs grown from CD45RA-depleted PBMCs have higher antigen-specificity, show greater fold expansion and have minimal NK cells. Further from some individuals the inventors were able to grow VSTs only if they first depleted RA+ T-cells from PBMCs.
  • Methods of the disclosure utilize antigen-presenting cells that present mixtures of peptides to T-cells.
  • Such “loaded” APCs are generated prior to exposure to peripheral blood T-cells for stimulation, and the generation of the loaded APCs may or may not be performed by the individual or entity that performs the stimulation step for the peripheral blood T-cells.
  • an effective amount of a library of peptides is provided to APCs as part of methods that ultimately generate therapeutic virus-specific T cells (VSTs) or antigen-specific T-cells.
  • VSTs virus-specific T cells
  • APCs prior to a stimulation step, APCs are exposed to a sufficient amount of the library of peptides.
  • the library in particular cases, comprises a mixture of peptides (“pepmixes”) that span part or all of the same antigen.
  • peptides for the APCs are non-natural.
  • the various peptides may come from any part of a given protein, but in specific cases the peptides span the length of the majority or all of the protein, wherein the sequence of the peptides overlap at least in part to facilitate coverage of the entire desired region of the specific antigen(s). In some cases the peptides span the length or one or more known epitopes or domains of the respective antigen to which the peptides correspond. Certain regions may be covered by peptides that span the length of the region, including a region such as a N-terminal domain, C-terminal domain, extracellular domain, or intracellular domain, for example.
  • the antigens from which the peptides are derived are antigens for EBV, CMV, adenovirus, vaccinia virus, and/or VZV that may be of any kind, but in specific embodiments the antigens are such that they allow for targeting for cytotoxic T-cells to medical conditions associated with EBV, CMV, adenovirus, vaccinia virus, and/or VZV infection, respectively.
  • the peptides are derived from, or have sequence that corresponds to, at least part of one or more antigens of at least one type of EBV, CMV, adenovirus, vaccinia virus, or VZV.
  • a pepmix library includes peptides corresponding to one or more antigens from a single virus, and those peptides may or may not provide sequence coverage across the entire antigen(s) in question.
  • a pepmix library includes peptides corresponding to one or more antigens from more than one virus, and those peptides may or may not provide sequence coverage across the entire antigen(s) in question.
  • the pepmix may or may not be enriched for peptides corresponding to one or more certain regions of one or more certain antigens or corresponding to the entirety of one or more certain antigens.
  • Pepmixes utilized in the disclosure may be from commercially available peptide libraries and/or may be synthetically generated. Examples of available libraries include those from JPT Technologies (Springfield, Va.) or Miltenyi Biotec (Auburn, Calif.). The skilled artisan based on known sequences of viral antigens, for example, would have sufficient information to be able to generate peptides that correspond to their exemplary, respective sequences. The skilled artisan, based on known sequences of antigens from these well-known viruses, for example, would have sufficient information to be able to generate peptides that correspond to their exemplary, respective sequences.
  • a library is comprised of peptides of a certain length that correspond to their respective antigens, although in some cases a library is comprised of a mixture of peptides with two or more different lengths.
  • the peptides may be of a certain length(s) and they may overlap in sequence of a certain amount, although there may be variability of length of overlap in some libraries.
  • the peptides are at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 or more amino acids in length, for example.
  • the peptides there is overlap among the peptides of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 amino acids in length, for example.
  • the peptides are 15 amino acids long and overlap one another by 11 amino acids.
  • a mixture of different peptides may include any ratio of the different peptides, although in some embodiments each particular peptide is present at substantially the same quantities in the mixture as another particular peptide.
  • a library may be enriched for one or more particular peptides, such as one or more peptides that are known to encode an epitope or a part thereof, for example.
  • the pepmix for a particular antigen protein comprise all possible HLA class I epitopes that are 8 to 10 amino acids long, for example.
  • longer peptides are utilized to cover all class II epitopes for a particular peptide.
  • a range of length of epitopes is 12-25 amino acids.
  • the present disclosure concerns the development of VSTs that target one or more antigens from at least one of EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • peripheral blood T-cells are initially stimulated with APCs that have been exposed to one or more peptides that span some or all of at least one viral antigen.
  • the antigenic peptides may be provided to the APCs as a library of peptide mixtures, and multiple libraries of pepmixes may be provided to the same collection of APCs.
  • the collection includes both immunodominant and subdominant antigens.
  • therapeutic T-cells are generated and may be provided to an individual that has a viral infection or is at risk of having a virus-associated medical condition that results indirectly or directly from a viral infection or are provided to an individual that has a non-virally infected tumor.
  • peripheral blood T-cells are mixed with APCs that are loaded with a library of peptides that span part or all of one or more viral antigens from one or more viruses.
  • the T-cells reside within a population of PBMCs.
  • the source of the peripheral blood T-cells may be of any kind, in specific embodiments the source is PBMCs, and in some cases a plurality of PBMCs are utilized in the methods, wherein the plurality comprises the peripheral blood T-cells.
  • Peripheral blood T-cells may be isolated or purified at least in part from PBMCs.
  • the PBMCs are non-adherent, and in some cases the PBMCs are CD45RA-depleted (wherein the depletion occurs prior to exposure of the PBMCs to the APCs).
  • the peripheral blood T-cells have reduced numbers of CD45RA-positive cells in comparison to a normal standard.
  • the peripheral blood T-cells or PBMCs may be depleted for certain cells by using standard means in the art including, for example, magnetic labeling and separation (for example, using Miltenyi® Biotec columns or StemSepTM magnetic beads).
  • the term “depleted” as used herein refers to the peripheral blood T-cells or PBMCs having substantially no CD45RA-positive cells therein. In some cases, “depleted” refers to there being a reduction of a certain percentage of CD45RA-positive cells compared to the numbers of those cells in an original collection of peripheral blood T-cells or PBMCs.
  • the number of CD45RA-positive cells are reduced from an original collection of peripheral blood T-cells or PBMCs because they are manipulated specifically to remove CD45RA-positive cells. In some cases, there is at least a 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% reduction of CD45RA-positive and/or CD45RO-positive cells from an original collection of peripheral blood T-cells or PBMCs following manipulation of the original collection to remove the CD45RA-positive cells. In some embodiments, myeloid cells may be removed using magnetic beads or plastic adherence.
  • there is a method of generating T-cells that target at least one antigen from EBV, CMV, adenovirus, Vaccinia, and/or VZV and this occurs generally by contacting a plurality of PBMCs with a plurality of APCs loaded for peptides from a library of peptides that correspond to one or more particular viral antigens from EBV, CMV, adenovirus, Vaccinia, and/or VZV.
  • the exposure of the two populations of cells allows for expansion of the T-cells.
  • the stimulation step(s) occurs in the presence of one or more particular cytokines.
  • the one or more cytokines are IL-7 and/or IL-15, although in alternative embodiments the cytokine(s) are selected from the group consisting of IL-2, IL-15, IL-7, IL-21, IL-12, IL-6, IL-4, and a combination thereof. In specific embodiments, one or more steps of the methods do not occur in the presence of IL-2, IL-4, IL-6, IL-7, IL-12, and/or IL-21, although alternatively IL-2, IL-4, IL-6, IL-7, IL-12, and/or IL-21 may be utilized. Reference to the presence of a cytokine is to presence of exogenously added cytokine, i.e.
  • the peptides are further defined as peptides that overlap in sequence to span part or all of a viral antigen that is not a HPV antigen.
  • the peptides overlap by at least 10 amino acids, and particularly 11, and in some embodiments the peptides are at least 12 or more amino acids in length, and particularly 15 amino acids in length.
  • Interleukin 6 50 to 150 ng/ml, one of about 50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml, 100 ng/ml, 110 ng/ml, 120 ng/ml, 130 ng/ml, 140 ng/ml or 150 ng/ml;
  • Interleukin 7 5 to 15 ng/ml, one of about 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 9 ng/ml, 10 ng/ml, 11 ng/ml, 12 ng/ml, 13 ng/ml, 14 ng/ml or 15 ng/ml;
  • Interleukin 12 5 to 15 ng/ml, one of about 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 9 ng/ml, 10 ng/ml, 11 ng/ml, 12 ng/ml, 13 ng/ml, 14 ng/ml or 15 ng/ml;
  • Interleukin 15 5 to 15 ng/ml, one of about 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 9 ng/ml, 10 ng/ml, 11 ng/ml, 12 ng/ml, 13 ng/ml, 14 ng/ml or 15 ng/ml.
  • Table 1 below provides examples of certain embodiments of methods of the disclosure.
  • a population of T-cells (wherein the population may comprise some, a majority, or substantially all T-cells or wherein the population of T-cells is within another population of cells, such as within PBMCs) is exposed to a population of APCs to generate T cell lines having particular characteristics, including at least: a) effectiveness at targeting viral antigen(s); b) polyclonality; c) TH1 bias; d) minimally differentiated memory type; or e) a combination thereof.
  • the cells may be minimally differentiated, but in some cases they may not all be and a majority may be somewhat differentiated.
  • T-cells are stimulated more than once, and different stimulation steps may or may not expose the population of cells to the same conditions.
  • a first stimulation has conditions different from a subsequent stimulation, including a second stimulation and/or a third stimulation.
  • a first stimulation step of the method utilizes APCs that are pepmix-loaded DCs or pepmix-loaded PBMCs and utilizes IL-7 and IL-15, although in alternative embodiments the step utilizes one or more cytokines selected from IL15, IL-7, IL21, IL12, IL-6, and/or IL-4. This stimulation step may optionally be repeated one or more times.
  • the peripheral blood T-cells or PBMCs
  • a stimulation step that is subsequent to the first stimulation step may be exposed to pepmix-loaded DCs or pepmix-loaded PBMCs and/or pepmix-pulsed autologous activated T-cells and/or HLA-negative costimulatory cells.
  • pepmix-loaded DCs or pepmix-loaded PBMCs and/or pepmix-pulsed autologous activated T-cells and/or HLA-negative costimulatory cells.
  • pepmix-loaded DCs or pepmix-loaded PBMCs and/or pepmix-pulsed autologous activated T-cells and/or HLA-negative costimulatory cells.
  • pepmix-loaded DCs or pepmix-loaded PBMCs and/or pepmix-pulsed autologous activated T-cells and/or HLA-negative costimulatory cells.
  • pepmix-pulsed AATCs combined with HLA-ve costimulatory cells.
  • a third stimulation may be required using the same antigen-presenting
  • Costimulatory cells that may be utilized in any stimulation step include at least cells that express CD86, 4-1BB, and/or CD83 and/or cells that are HLA-negative lymphoblastoid cells.
  • the costimulatory cells may be gene-modified K562 cells.
  • the cells in culture are modified.
  • the cells are modified to harbor a polynucleotide that expresses a gene product that renders the cells effective or more effective for a specific purpose or function, such as effective or more effective for targeting a particular target and/or enhanced in function for T-cell-mediated cytotoxicity, for example.
  • the cells are modified to express a certain non-natural receptor that allows the T-cells to effectively or more effectively target a desired target cell, such as one that expresses a certain antigen.
  • the cells are modified to express a chimeric antigen receptor (CAR), and so forth.
  • CAR chimeric antigen receptor
  • the cells may be modified to express an expression vector (that may be viral (including retroviral, lentiviral, adenoviral, adeno-associated viral, and so forth) or non-viral, e.g., a transposon such as piggyBac) during the method at specific time points, such as the vector being introduced between day 2 and 5 of culture, for example so that the vector is expressed in T-cells with long-term repopulation potential.
  • an expression vector that may be viral (including retroviral, lentiviral, adenoviral, adeno-associated viral, and so forth) or non-viral, e.g., a transposon such as piggyBac
  • the cells are exposed to the expression vector within about 3 days after each stimulation, but in such cases the modification occurs in more differentiated T-cells that have less long term potential (which in specific circumstances is desirable, such as if long term expression of gene-modified cells is not desirable, as in the case where the transgene has potential toxicity, for example).
  • the cells are modified to express a CAR that targets a cancer antigen, such as EphA2, HER2, GD2, Glypican-3, 5T4, 8H9, ⁇ v ⁇ 6 integrin, B cell maturation antigen (BCMA) B7-H3, B7-H6, CAIX, CA9, CD19, CD20, CD22, kappa light chain, CD30, CD33, CD38, CD44, CD44v6, CD44v7/8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, ERBB3, ERBB4, ErbB3/4, FAP, FAR, FBP, fetal AchR, Folate Receptor a, GD2, GD3, HLA-AI MAGE A1, HLA-A2, IL11Ra, IL13Ra2, KDR, Lambda, Lewis-Y, MCSP, Mesothelin, Muc1, Mu
  • cells produced by methods of the disclosure are provided to an individual in need thereof for treatment of a medical condition or to target a viral infection or virus-associated cancer or non-virus-associated cancer in which no symptoms of a medical condition are detectable or have manifested.
  • treatment includes any beneficial or desirable effect on the symptoms or pathology of a disease or pathological condition, and may include even minimal reductions in one or more measurable markers of the disease or condition being treated. Treatment can involve optionally either the reduction or amelioration of symptoms of the disease or condition, or the delaying of the progression of the disease or condition. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
  • the therapeutic T-cells are utilized to treat virus-associated disease caused directly or indirectly by a single non-HPV virus or are otherwise provided to an individual that is seropositive for a single non-HPV virus. In other cases, the therapeutic T-cells are utilized to treat disease(s) caused directly or indirectly by more than one virus
  • each T-cell and its progeny has specificity for only one peptide in one antigen from one virus, and upon production of the collection of therapeutic T-cells, one expands a population of T-cell clones that together have multi-specificity, such as for multiple epitopes in each viral antigen, for example.
  • a therapeutically effective amount of the VSTs generated thereby are administered to an individual, for example, an individual known to have or suspected of having or susceptible to having disease associated with EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • the cells are administered by injection, such as intravenous, intramuscular, intradermal, subcutaneous, intraperitoneal injection, and so forth, for example.
  • the VSTs may be polyclonal CD4+ and CD8+ VSTs.
  • the PBMCs may be allogeneic to the individual or are autologous to the individual.
  • neoplasms are treated with cells of the disclosure, and the neoplasm may be benign, malignant, or a premalignant lesion that can lead to cancer.
  • an individual may be treated with cells produced by methods of the disclosure at the premalignant lesion stage and/or after the lesion becomes malignant.
  • the individual may have early or late stage cancer, and the skilled artisan is aware that the methods of producing the cells may be tailored for such different stages of cancer, such as by utilizing peptides for the APCs that are from antigens associated with early vs. late stage cancer.
  • the cancer may be primary, metastatic, recurrent, refractory, and so forth.
  • cells specific for EBV, CMV, adenovirus, vaccinia virus, and/or VZV have activity for individuals that are positive for EBV, CMV, adenovirus, vaccinia virus, and/or VZV, respectively.
  • cells specific for one of the viruses encompassed herein are gene-modified with a receptor for a non-viral tumor and then infused to treat that non-viral tumor, so that the virus or viral antigen can be used to stimulate expansion of the T-cells in vivo, for example by vaccination or using oncolytic viruses or endogenous viruses.
  • the outcome of administration of T-cells expanded through such APCs is determined by whether the individual has been exposed to the virus. For example, in particular embodiments if an individual is infected with a certain virus, only T-cells specific for that virus will respond, and this is because the infection will initially have stimulated a T-cell response to that virus. Those T-cells will expand in the individual and then become memory T-cells and would be at higher numbers than T-cells specific for another virus that have never been activated.
  • the individual being treated may be known to have a virus-associated disease, suspected of having a virus-associated disease, or at risk for a virus-associated disease.
  • An individual being treated may have the presence of the virus but there are not yet any deleterious symptoms of a virus-related medical condition.
  • the individual may be at risk for a non-HPV virus-associated disease given an environment or event that exposes them to the non-HPV virus.
  • one or more administrations of the cells produced by methods of the disclosure are provided to an individual in need thereof.
  • the length of time between multiple administrations may be of any suitable duration so long as subsequent administrations are effective against the cancer, including on the order of days, weeks, months, or years.
  • the antigen to which the cells are targeted may or may not be the same antigen as the cells utilized in earlier administration(s). For example, in a first administration of cells, they may target one viral antigen, whereas in another administration of cells, the cells target a different antigen, including from a different virus, in at least some cases.
  • an individual is optionally determined to have viral infection by any suitable means in the art.
  • infection diagnosis methods such as DNA tests utilizing PCR, Southern blot hybridization, in situ hybridization, and these methods may or may not be used in conjunction with other methods, for example.
  • the individual is immunocompromised (which for example, may be defined as an individual whose ability to fight infectious disease or cancer with the immune system is compromised or entirely absent).
  • the immunocompromised individual has had a stem cell transplant (including hematopoietic stem cell transplantation), has had an organ transplant and/or has received one or more cancer treatments, including chemotherapy or radiation, or has been infected with HIV, for example.
  • the individual has acquired or inherited immune deficiency disorder.
  • those that are immunocompromised by their disease and/or its treatment are provided methods and/or compositions of the disclosure.
  • Epstein-Barr virus also called human herpesvirus 4 (HHV-4)
  • HHV-4 human herpesvirus 4
  • EBV causes infectious mononucleosis, some forms of cancer (including Hodgkin's lymphoma, Burkitt's lymphoma, gastric cancer, nasopharyngeal cancer, NK/T lymphoma, diffuse large B-cell lymphoma, and leiomyosarcoma, at least), and certain conditions associated with human immunodeficiency virus (HIV), including hairy leukoplakia and central nervous system lymphomas, as examples.
  • EBV infection or one or more EBV-associated medical conditions are treated using the cells.
  • EBV encodes about 90 proteins, a limited fraction of these are expressed in EBV-associated malignancies. About 80 genes are involved in the viral lytic cycle and about 9 genes are associated with virus latency. In some tumors only 4 EBV genes are expressed and in others only 2 are expressed. Recently some tumors have been show to undergo abortive virus replication and express early viral proteins and they have also been show to express unexpected transcripts from the lytic cycle. All of these provide transcripts may encode potential target antigens for VSTs. Generally one can target LMP1, LMP2, BARF1 and EBNA1 that are considered EBV type 2 latency antigens. However, in some cases one may also target early viral proteins, such as those encoded by BZLF1, BRLF1, BMLF1 or unexpected transcripts such as BXLF1/2, for example.
  • Cytomegalovirus also known as human herpesvirus-5, is a virus in the family Herpesviridae. CMV infection normally does not result in disease unless the infected individual is an infant or is immune-compromised (such as an organ or tissue or cell transplant recipient, including after allogeneic marrow transplantation, for example). Although any antigen of CMV may be targeted with cells produced by methods of the disclosure, in specific embodiments the antigen is the immediate early antigen, IE1, and the tegument protein, pp65.
  • IE1 immediate early antigen
  • tegument protein pp65.
  • Adenoviruses can cause common cold, sore throat (pharyngitis), bronchitis, pneumonia, diarrhea, pink eye (conjunctivitis), fever, cystitis, gastroenteritis, and neurologic disease. Healthy individuals are rarely subject to adenovirus-associated serious illness or death. However, infants and people with weakened immune systems, or existing respiratory or cardiac disease, are at higher risk of developing severe illness from an adenovirus infection.
  • Cells of the disclosure may be targeted for any adenovirus antigen, but in specific embodiments the antigen is hexon and/or penton.
  • vaccinia virus (also called VACV or VV) is a poxvirus that causes cow pox in cows but has provided an effective vaccine for smallpox, which may be treated with cells produced by methods of the disclosure.
  • any antigen of vaccinia virus may be targeted with cells produced by methods of the disclosure, in particular cases the antigens are E3L, A10L/121L, H3L/093L, G5R/074R, C7L/018R, B22R/189R, D8L, E5R, E4L, f17R, A17L, and/or L4R.
  • VZV Varicella zoster virus
  • VZV is one of eight herpesviruses known to infect humans and vertebrates. VZV causes chickenpox in children, teens and young adults, and it causes herpes zoster (shingles) in adults and some children. VZV is known by many names, including chickenpox virus, varicella virus, zoster virus, and human herpesvirus type 3 (HHV-3).
  • VZV antigens that may be utilized as a source of peptides (or sequence thereof) include any of the capsid, envelope, or soluble antigens. Specific examples include V antigen, S antigen, 1E61, 1E62, 1E63, gE and ORF10.
  • Vaccines for VZV comprise live attenuated viruses that cause limited infection in humans.
  • the term “pharmaceutical composition” relates to a composition for administration to an individual.
  • the pharmaceutical composition comprises a composition comprising therapeutic immune cells for parenteral, transdermal, intraluminal, intra-arterial, intrathecal or intravenous administration or for direct injection into a cancer. It is in particular envisaged that the pharmaceutical composition is administered to the individual via infusion or injection. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, subcutaneous, intraperitoneal, intramuscular, topical or intradermal administration.
  • the pharmaceutical composition of the present disclosure may further comprise a pharmaceutically acceptable carrier.
  • suitable pharmaceutical carriers include phosphate buffered saline solutions, and the cells may be in a sterile buffer suitable for infusion with a protein such as human serum albumin for infusion.
  • the dosage regimen will be determined by the clinical protocol that has been approved by the appropriate local and federal regulatory agents. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size and body surface area, for example. A particular dosage for administration might be in the range of from 5 ⁇ 10 6 per m 2 to 5 ⁇ 10 9 per m 2 . Progress can be monitored by periodic assessment.
  • methods of the present disclosure for clinical aspects are combined with other agents effective in the treatment of one or more medical conditions with which the virus is associated.
  • compositions described herein may be comprised in a kit.
  • a library of pepmixes may be comprised in a kit, any type of cells may be provided in the kit, and/or reagents for manipulation of pepmixes and/or cells may be provided in the kit.
  • Cytokines or means of producing them may be included in the kit.
  • Cell culture reagents and/or apparatus(es) may be included.
  • the component(s) are provided in suitable container means.
  • kits may comprise a suitably aliquoted compositions of the present disclosure.
  • the components of the kits may be packaged either in aqueous media or in lyophilized form.
  • the container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial.
  • the kits of the present invention also will typically include a means for containing the components in close confinement for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained.
  • the components of the kit may be provided as dried powder(s).
  • the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.
  • reagents and/or devices to detect viral infection may be included in the kit. Examples include swabs, spatulas, cytobrushes, slides, cover slips, cytology sample collection receptacle, and so forth. Additional drugs for viral infection may be included in the kit.
  • T-cells including polyclonal (for example, CD4+ and CD8+) VSTs, that are consistently specific for a variety of antigens derived from one or more human viruses that can prove fatal.
  • the disclosure is readily adaptable to clinical implementation and can be used as an “off the shelf” antiviral agent, including for EBV, CMV, adenovirus, vaccinia virus, and/or VZV.
  • the methods and compositions are readily adaptable to clinical implementation and are useful as a safe and effective antiviral agent for individuals.
  • peripheral blood T-cells are stimulated with monocyte-derived dendritic cells loaded with pepmixes (peptide libraries of 15-mers overlapping by 11 amino acids (aa)) spanning the antigen protein, in the presence or absence of specific accessory cytokines.
  • the resulting T-cell lines may be further expanded with pepmix-loaded activated cells.
  • T-cell lines possess the desirable characteristics of polyclonality, multiple T-cell subset representation (including the memory compartment) and a TH1 bias, and eliminate viral targets.
  • the disclosure provides that it is possible to robustly generate viral-directed T-cell lines from patients with virus-associated cancers. Because the technique is scalable and good-manufacturing procedures-compliant, these lines are useful for adoptive cellular immunotherapy of patients with virus-related medical condition(s).
  • DCs are loaded with viral antigen(s) pepmix libraries.
  • the cell lines are able to recognize one or more viral antigens.
  • expansion of the T-cells occurs in the presence of IL-7 and IL-15 but not IL-2.
  • the presence of IL-7 and IL-15 in conditions for the method may or may not be at each step of stimulation and expansion.
  • expansion of the virus-specific T-cells after initial generation/expansion with DCs utilizes autologous, polyclonal activated T-cells loaded with pepmixes, in the presence of costimulatory cells (CD80/CD86/CD83/4-1BBL or others), and IL-7 and IL-15. Employing these conditions, T-cell expansion occurs at a more rapid rate than in the absence of such conditions and occurs without loss of specificity.
  • the method(s) are effective for at least EBV, CMV, adenovirus, VZV, vaccinia virus, HIV, BK and HHV6, although the methods may be effective for other viruses.
  • Modifications of these methods compared to those known in the art address deficiencies, such as low frequency of viral-specific antigen-specific T-cells and/or high frequency of NK cells in some viral-specific antigen-specific T cell lines, for example.
  • PBMCs utilized as a source of T-cells in steps of the method may be depleted for certain cells, such as depletion of CD45RA+ cells, for example.
  • Culture of the cells at any step of the method may occur in the presence of certain cytokines or combinations thereof, and certain levels of these cytokine(s) may need to be achieved.
  • one or more steps of the method occurs in high (100 ng to 1000 ng per mL) doses of IL15 and IL-7.
  • costimulatory cells are utilized. Although a variety of costimulatory cells may be useful, in specific embodiments the cells are HLA-negative LCLs.
  • FIG. 1 describes steps of the methods of the disclosure for generating virus-specific T-cells.
  • PBMCs which may or may not be depleted for certain cells, such as CD45RA+ T-cells
  • viral peptides as an example for EBV
  • peptides that encompass part or all of LMP1, LMP2, EBNA1, and/or BARF1 are utilized.
  • cytokines including certain one or more cytokines, including certain combinations of cytokines.
  • IL7 and/or IL15 including human IL15 (IL15H) are employed.
  • this first step there may or may not also be costimulatory cells, including irradiated HLA-ve LCLs.
  • the cells are exposed to peptide-pulsed irradiated autologous antigen T-cells and in at least some cases also costimulatory cells, such as HLA-ve LCLs.
  • This step may or may not occur in the presence of one or more cytokines, including certain combinations, such as IL7 and/or IL15, including IL15H.
  • the cells may be used or may be cryopreserved.
  • FIG. 2 shows results of improved specificity of EB viral-specific T-cells (EBVSTs) developed in the presence of IL-7 and IL-15 instead of IL-4 and IL-7.
  • EBVSTs EB viral-specific T-cells
  • methods of the disclosure are developed for lymphoma patients, whose T-cells are anergic to viral antigens expressed in their tumor cells.
  • Specific embodiments of methods of the disclosure improve the antigen-specificity of lymphoma patient EBVSTs and allow anergy to be overcome by utilizing at least IL-15 in one or more steps ( FIG. 3 ).
  • using IL-15 instead of IL-4 increases the frequency of antigen-specific T-cells in patient EBVSTs.
  • FIG. 4 demonstrates that high doses of IL-15 increase central memory EBVSTs.
  • NK cell outgrowth in EBVSTs from some patients and healthy donors was addressed.
  • NK cell populations seem to be exacerbated in lines grown in IL-15 and IL-7) and/or could be attributable to the use of K562cs (irradiated HLA-negative K562 cells genetically modified to express CD80, CD83, CD86, and 4-1BBL) ( FIG. 6 ) or the combination of IL15 and K562 cells.
  • K562cs irradiated HLA-negative K562 cells genetically modified to express CD80, CD83, CD86, and 4-1BBL
  • CD45RA is a na ⁇ ve T-cell marker that is also expressed on natural T-regulatory cells and NK cells, so such depletion should remove the NK cells.
  • CD45RO-positive cells are enriched through depletion of cells expressing CD45RA.
  • this step should remove T regulatory cells that can inhibit the outgrowth of antigen-specific T-cells, especially in cancer patients, and also removes na ⁇ ve cells that can grow as bystander cells and dilute the antigen-specific T-cells.
  • Depletion may occur by any suitable method, but in specific embodiments depletion occurs using magnetic labeling and separation (for example, using Miltenyi® Biotec columns). Use of antibody to deplete cells using magnetic beads or nanobubbles may also occur.
  • FIG. 7 Generation of pepmix-activated EBVSTs from CD45RA-depleted PBMCs is illustrated in FIG. 7 . As shown therein, whole PBMCs are depleted of CD45RA, and beginning day 0 or day 1 the first stimulation (S1) EBVpepmix is added to the depleted cells in the presence of IL-7 and IL-15 to produce EBVSTs.
  • S1 first stimulation
  • FIG. 8 demonstrates the results that CD45RA depletion (CD45RA+ PBMC from healthy donors were depleted using Miltenyi® columns and GMP grade CD45RA-conjugated beads) decreases the frequency of CD3-CD56+ NK cells in EBVSTs. Following this, there is increased proliferation of EBVSTs ( FIG. 9 ).
  • FIG. 10 illustrates the enhanced fold expansion of EBVSTs following CD45RA depletion from healthy donors at the end of a second stimulation step.
  • the CD45RA depletion enhances antigen specificity of EBVSTs at the end of a second stimulation (for example, day 16) ( FIGS. 11 and 12 , both showing data for healthy donors).
  • the increased antigen specificity of CD45RA depleted EBVSTs is sustained after a third stimulation ( FIG. 13 ).
  • FIG. 14 shows the total NK cell population at the end of a second stimulation step in five lymphoma patients, demonstrating that CD45RA depletion decreases NK cell population outgrowth in lymphoma patient EBVSTs, and this depletion increased the frequency of the antigen-specific T-cells (illustrated by IFN- ⁇ release ELIspot assay at the end of a second stimulation) ( FIG. 15 ). This experiment was performed in the absence of dendritic cells for the first stimulation.
  • CD45RA depletion increased antigen specificity in EBVSTs from lymphoma patients ( FIG. 16 ). Proliferation of the lymphoma patients' EBVSTs is demonstrated in FIG. 17 . Furthermore, CD45RA depletion enhanced cytolytic activity against pepmix-pulsed autologous activated T-cells (aATCs); percentage lysis was observed at effector to target ratio of 20:1 ( FIG. 18 ).
  • FIG. 19 illustrates the generation of multivirus-specific T-cells specific for EBV, CMV, Adenovirus, BKG virus, and HHV6.
  • the pepmixes include peptides from EBNA1, LMP2, and BZLF1 for EBV; IE and pp65 for CMV; hexon and penton for Adenovirus, LT and VP1 for BK, and U11, U14, and U90 for HHV6.
  • a pepmix comprising peptides that span part or all of each of these viral antigens is exposed to PBMCs at day 0 in the presence of IL7 and high dose IL15.
  • pepmix-activated ATCs and costimulatory cells are exposed to the cells in the presence of IL7 and high dose IL15.
  • another round of pepmix-activated ATCs and costimulatory cells are exposed to the cells in the presence of IL7 and IL15H, ultimately producing multivirus (m)VSTs (D23) cells.
  • FIG. 20 demonstrates the total fold expansion at and after subsequent stimulation steps of embodiments of the method.
  • the antigen specificity of the multivirus-specific T-cells was examined, and T-cells with specificity for all 5 viruses expanded ( FIG. 21 ).
  • CAR-modified T-cells may be generated using methods of the disclosure.
  • FIG. 22 demonstrates proliferation of VZV-specific VSTs after a first stimulation, again comparing methods of the disclosure to those that employ dendritic cells; there was no significant difference in proliferation between DC-initiated VSTs and PBMC-initiated VSTs or in expansion of the VZVSTs after the second stimulation ( FIG. 23 ).
  • FIGS. 24 and 25 demonstrate specificity of the VZV-specific VSTs after a first stimulation at day 8 ( FIG. 24 ) and after a second stimulation at day 16 ( FIG. 25 ). In specific cases, and without being bound by theory, such an outcome is because if the antigens are not expressed in tumor cells they are not anergic.
  • EBVSTs expanded with dendritic cells in IL4/7 are comparable to methods encompassed herein.
  • a high dose IL-15 and IL-7 increased the fold expansion of EBVST in healthy donors and patients as well as increased the frequency of EBV-antigen-specific T-cells in both healthy donors and patients, in addition to eliminating the requirement for dendritic cells in first stimulations.
  • the strategy was effective for multiple viruses (EBV, CMV, adenovirus, BK virus, HHV6 and VZV) and was effective for retrovirally-transduced virus-specific T-cells.
  • EBV EBV, CMV, adenovirus, BK virus, HHV6 and VZV
  • T cells specific for HIV antigen are produced with methods of the disclosure.
  • FIG. 26 illustrates one embodiment of manufacturing of HIV-specific T cells from HIV seropositive donors.
  • FIG. 27 shows optimal expansion of the cells with K562 cells in a second stimulation. Therein, results are shown after only 2 stimulations (15-16 days)+1 week for DCs. Expansion in presence of K562 is higher than without K562 during the second stimulation.
  • FIG. 28 demonstrates that in the presence of K562, HIV antigen-specific T cells (HIVSTs) expanded to clinically relevant numbers after only 2 stimulations.
  • HIVSTs HIV antigen-specific T cells
  • FIG. 29 shows that HIVSTs are specific for multiple HIV antigens.
  • the specificity of HIVSTs was assessed by interferon (IFN)- ⁇ secretion in response to individual pepmixes for each HIV antigen in an ELIspot assay.
  • the specificity of HIVSTs was assessed by interferon (IFN)- ⁇ secretion in response to individual PepMixes for each HIV antigen in ELIspot assay. All of the lines were multispecific for all 3 antigens.
  • equivalent antigen specificity was observed post first stimulation. Specificity was not lost by adding K562 during a second stimulation. There was an advantage for High dose IL-15 by the end of the second stimulation. For the second validation, there was high background after the first stimulation. Greater specificity was observed for GAG, POL and NEF in ARM2 (High IL-15) than in ARM1 (low IL-15).
  • a negative control included ⁇ 10 spots per 1e5 HIVSTs.
  • FIG. 30 shows that HIVSTs comprise mixed CD4+ and CD8+ T cells.
  • the lines were predominantly CD3+CD8+ T cells, although there were a proportion of CD4+ T cells.
  • the T cell lines contained a subpopulation of CD3-CD56+ NK cells.
  • In the first validation there was a similar phenotype with more CD3-CD56+CD16+ NK cells and fewer CD3+ T-cells in ARM1.
  • ARM2 High IL-15
  • CD4 T cells are known to provide CD8 T cell help, aiding in memory, persistence, and effector functions, it is critical that any T cell immunotherapy approach for HIV utilizes CD4 T cells. While the infusion of a small percentage of CD4 T cells may seem counterintuitive, non-CD4-depleted T cells have been infused in the past, and no significant increase in viral load was observed.
  • FIG. 31 demonstrates that HIVSTscan lyse antigen-pulsed and HIV-infected targets.
  • the inventors incubated the HIVSTs with a panel of 51 Chromium ( 51 Cr)-labeled autologous pepmix-ATCs target cells.
  • HIVSTs were specific because lysis of activated autologous target cells alone was not observed.
  • the ability of HIVSTs to lyse antigen-expressing targets was measured using an 4-hour 51 Chromium-release assay.
  • Target cells consisted of autologous PHA-blasts that were pulsed with either media or Gag, Pol, or Nef PepMixes and were loaded with chromium. HIVSTs were cultured with target cells pulsed with only the antigens they were specific for, which was predetermined by IFN- ⁇ ELIspot assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
US16/331,494 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells Abandoned US20190194619A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/331,494 US20190194619A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395438P 2016-09-16 2016-09-16
PCT/US2017/051284 WO2018052947A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells
US16/331,494 US20190194619A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/051284 A-371-Of-International WO2018052947A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/661,060 Continuation US20220251509A1 (en) 2016-09-16 2022-04-28 Platform for activation and expansion of virus-specific t-cells

Publications (1)

Publication Number Publication Date
US20190194619A1 true US20190194619A1 (en) 2019-06-27

Family

ID=61619728

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/331,494 Abandoned US20190194619A1 (en) 2016-09-16 2017-09-13 Platform for activation and expansion of virus-specific t-cells
US17/661,060 Pending US20220251509A1 (en) 2016-09-16 2022-04-28 Platform for activation and expansion of virus-specific t-cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/661,060 Pending US20220251509A1 (en) 2016-09-16 2022-04-28 Platform for activation and expansion of virus-specific t-cells

Country Status (9)

Country Link
US (2) US20190194619A1 (zh)
EP (1) EP3512531A4 (zh)
JP (1) JP7002769B2 (zh)
KR (1) KR102501827B1 (zh)
CN (1) CN110177558A (zh)
AU (1) AU2017326173B2 (zh)
CA (1) CA3036966A1 (zh)
TW (1) TWI780069B (zh)
WO (1) WO2018052947A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056285A1 (en) * 2020-09-10 2022-03-17 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
WO2022232797A3 (en) * 2021-04-27 2022-12-15 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US9642906B2 (en) 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
TW202011977A (zh) * 2018-04-20 2020-04-01 貝勒醫學院 溶瘤病毒療法及免疫療法
CN108841792A (zh) * 2018-06-14 2018-11-20 浙江大学 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
EP3849571A4 (en) * 2018-09-10 2022-10-05 Atara Biotherapeutics, Inc. METHODS FOR EXPANSION OF ANTIGEN-SPECIFIC CAR-T CELLS, COMPOSITIONS AND USES RELATED THERETO
US10772914B1 (en) * 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
WO2021101466A1 (en) * 2019-11-19 2021-05-27 Acibadem Labmed Sağlik Hi̇zmetleri̇ A.Ş. A method for producing multivirus specific t cells
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
CN116391030A (zh) * 2020-10-28 2023-07-04 Tsd 生命科学有限公司 诱导异质免疫细胞趋化的转化免疫细胞
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155594A1 (en) 2001-03-27 2002-10-24 Hsieh Helen V. Method and apparatus for culturing cells
PL1956080T3 (pl) * 2005-08-08 2012-02-29 Ospedale San Raffaele Srl Zastosowanie IL-7 oraz IL-15 do genetycznej modyfikacji komórek T pamięci
EP3357338A1 (en) * 2007-03-30 2018-08-08 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2065462A1 (en) * 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
US10351824B2 (en) * 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
ES2748652T3 (es) * 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
KR101545217B1 (ko) * 2012-10-29 2015-08-18 연세대학교 산학협력단 줄기세포의 미분화 배양 및 분화 증진을 위한 폴리도파민-펩타이드 고정화 표면 기질 및 그 제조 방법
CN105335280A (zh) * 2014-07-16 2016-02-17 北京奇虎科技有限公司 程序性能测试方法和装置
IL308324A (en) * 2014-09-19 2024-01-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US20210380943A1 (en) * 2015-03-20 2021-12-09 Children's National Medical Center Generating hpv antigen-specific t cells from a naïve t cell population
CN107835690A (zh) * 2015-05-12 2018-03-23 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗埃巴病毒相关淋巴细胞增生性病症的方法
EP3307875B1 (en) * 2015-06-09 2021-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
MX2019000022A (es) * 2016-06-27 2019-09-18 Yeda Res & Dev Células veto generadas a partir de linfocitos t de memoria.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056285A1 (en) * 2020-09-10 2022-03-17 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
WO2022232797A3 (en) * 2021-04-27 2022-12-15 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors

Also Published As

Publication number Publication date
US20220251509A1 (en) 2022-08-11
JP7002769B2 (ja) 2022-02-04
EP3512531A1 (en) 2019-07-24
CN110177558A (zh) 2019-08-27
AU2017326173A1 (en) 2019-04-11
JP2019531722A (ja) 2019-11-07
AU2017326173B2 (en) 2022-08-18
KR20190051039A (ko) 2019-05-14
CA3036966A1 (en) 2018-03-22
TW201814041A (zh) 2018-04-16
EP3512531A4 (en) 2020-03-11
TWI780069B (zh) 2022-10-11
WO2018052947A1 (en) 2018-03-22
KR102501827B1 (ko) 2023-02-22

Similar Documents

Publication Publication Date Title
US20220251509A1 (en) Platform for activation and expansion of virus-specific t-cells
US10500265B2 (en) Generation of HPV-specific T-cells
US11118164B2 (en) Pepmixes to generate multiviral CTLs with broad specificity
Tanaka et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells
Leen et al. Antiviral T‐cell therapy
Gottschalk et al. Adoptive T-cell immunotherapy
US10857182B2 (en) Generation and use in adoptive immunotherapy of stem cell-like memory T cells
Rooney et al. T lymphocytes targeting native receptors
US10772914B1 (en) EBV-specific immune cells
NZ791258A (en) Platform for activation and expansion of virus-specific t-cells
Emery et al. Immunotherapy and vaccination after transplant: the present, the future
Sharma et al. Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma
Withers Third-party virus-specific T-cells can provide long-term viral control without toxicity in allogeneic haemopoietic stem cell transplant patients with recurrent or refractory viral infection
Zecca et al. Possible alternatives to antimicrobial therapies
Drawz et al. Adoptive immunotherapy
Bollard et al. Adoptive T‐cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYLOR COLLEGE OF MEDICINE, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROONEY, CLIONA M.;DOYLE, NATALIA LAPTEVA;SHARMA, SANDHYA;AND OTHERS;SIGNING DATES FROM 20170127 TO 20170130;REEL/FRAME:048536/0794

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: SPECIAL NEW

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION